Guselkumab for Psoriasis Vulgaris (Plaque Psoriasis)

Phase-Based Progress Estimates
3
Effectiveness
3
Safety
Psoriasis Vulgaris (Plaque Psoriasis)+2 More
Guselkumab - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new psoriasis drug, guselkumab, to see if it is effective and safe.

Eligible Conditions
  • Psoriasis Vulgaris (Plaque Psoriasis)
  • Psoriasis

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: baseline and week 44

baseline and week 44
Lesional CD4+ T effector cells
Lesional CD8+ T effector cells

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Side Effects for

Ixekizumab
9%Injection site reaction
8%Upper respiratory tract infection
7%Nasopharyngitis
This histogram enumerates side effects from a completed 2020 Phase 4 trial (NCT03573323) in the Ixekizumab ARM group. Side effects include: Injection site reaction with 9%, Upper respiratory tract infection with 8%, Nasopharyngitis with 7%.

Trial Design

2 Treatment Groups

New-onset guttate psoriasis
1 of 2
Chronic plaque psoriasis
1 of 2
Experimental Treatment

25 Total Participants · 2 Treatment Groups

Primary Treatment: Guselkumab · No Placebo Group · Phase 4

New-onset guttate psoriasis
Drug
Experimental Group · 1 Intervention: Guselkumab · Intervention Types: Drug
Chronic plaque psoriasis
Drug
Experimental Group · 1 Intervention: Guselkumab · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Guselkumab
FDA approved

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline and week 44

Who is running the clinical trial?

University of California, San FranciscoLead Sponsor
2,262 Previous Clinical Trials
11,470,079 Total Patients Enrolled
5 Trials studying Psoriasis Vulgaris (Plaque Psoriasis)
124 Patients Enrolled for Psoriasis Vulgaris (Plaque Psoriasis)
Janssen Biotech, Inc.Industry Sponsor
29 Previous Clinical Trials
18,784 Total Patients Enrolled
Wilson Liao, MDPrincipal InvestigatorUniversity of California, San Francisco
4 Previous Clinical Trials
56 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are at least 18 years of age.
You have guttate psoriasis.
You have guttate psoriasis.
You are not likely to conceive due to male, post-menopausal, or using adequate contraceptive (barrier, hormonal, implant, or permanent sterilization methods).

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 19th, 2021

Last Reviewed: October 10th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.